Drug
Tacrolimus Targeted Half Dose
Tacrolimus Targeted Half Dose: highest development phase Post-Market, developed by Astellas. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Astellas
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tacrolimus targeted half-dose NCT02154854 | Post-Market | De Novo Transplant Disease |
Latest
No recent events.
Follow Tacrolimus Targeted Half Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.